ARCH:TSXV ACHFF:OTC
  • Home
  • About usOur story, our approach
  • Our Science Pipeline, research & publications
    • Our Key Platforms
      • MetaBlok™Treating, organ injury caused by inflammation
      • AB569Treatment for Respiratory Pseudomonas aeruginosa Infections
      • BORGPeptide Solid Surface Interface
      • MetaMx™Brain Tumor Initiating Cell Targeting
    • Our PublicationsPeer-reviewed scientific publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team Management & lead scientists
    • Our ManagementGovernance, Executive, Board of Directors and Advisors
    • Our Principal ScientistsLearn about the scientists behind our technologies
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub Investor relations, fundamentals
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us

Investor Information

Find key information for investors – management and investor relations contact details, Auditor, Transfer Agent and SEDAR Profile.

Arch Biopartners, Inc.

Richard Muruve
Chief Executive Officer
647-428-7031
This email address is being protected from spambots. You need JavaScript enabled to view it.

For investor relations inquiries,
please contact Richard Muruve 

 

Stock Information

View historical chart, quote and data

ARCH (TSX Venture Exchange)
TMX Money charts and historical data, (link opens in a new window)

Auditor

The Exchange Chartered Accountants LLP

Transfer Agent

TMX Equity Transfer Services Inc.

Sedar Profile

Arch Biopartners, (link opens in a new window)

Reports and Filings

See the Reports and Filings section on our website

Recent News

January 5th 2021

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Read More
December 29th 2020

Arch Biopartners Closes Non-Brokered Private Placement

Read More
Arch Biopartners
  • Home
  • About us
  • Our Science
    • Our Key Platforms
    • Our Publications
  • Our Team
    • Our Management
    • Our Principal Scientists
  • Investor Hub
    • Fundamentals
    • Reports and Filings
  • Contact Us
Contact us
+1 647 428 7031
info@archbiopartners.com
Mailing Address
27 St. Clair Ave East
P.O. Box 305
Toronto, Ontario
Canada M4T 2M5
Copyright Arch BioPartners 2020. All Rights Reserved. Legal notices.
PAGE TOP | TYPE SIZE | | RESET
Investor Information
  • Home
  • About us
  • Our Science
    • Our Key Platforms
      • MetaBlok™
      • AB569
      • BORG
      • MetaMx™
    • Our Publications
      • AB569
      • Brain Tumor Stem Cell Targeting
      • BORG Peptide Solid Surface Interface
      • Treatments for Inflammation
  • Our Team
    • Our Management
    • Our Principal Scientists
      • MetaBlok™ and MetaMx™
      • AB569 & Respiratory Pseudomonas
      • BORG Peptide
      • Treatments for Inflammation
  • Investor Hub
    • Fundamentals
      • Press Releases
      • Investor Information
      • Stock Performance
    • Reports and Filings
      • Management Discussion and Analysis
      • Annual and Quarterly Reports
      • Proxies and Information Circulars
      • Material Change Documents
      • Other SEDAR Filings
  • Contact Us